NCT05058924View on ClinicalTrials.gov

Low Molecular Weight hEparin vs. Aspirin Post-partum

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 29, 2021

Primary Completion Date

February 29, 2024

Study Completion Date

March 1, 2024

Conditions
Venous Thromboembolism
Interventions
DRUG

Prophylactic low molecular weight heparin

Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.

DRUG

Low molecular weight heparin and low-dose aspirin

Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.

Trial Locations (1)

M5G 1Z5

Mount Sinai Hospital, Toronto

All Listed Sponsors
lead

Mount Sinai Hospital, Canada

OTHER

NCT05058924 - Low Molecular Weight hEparin vs. Aspirin Post-partum | Biotech Hunter | Biotech Hunter